EGFR and lung adenocarcinoma: The secondary T790M EGFR mutation appears in advanced lung adenocarcinoma with acquired resistance due to prior bevacizumab treatment combined with erlotinib or afatinib, and osimertinib is administered as a subsequent therapy for T790M-positive patients (15, 16).